OncoMatch/Clinical Trials/NCT06645678
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Is NCT06645678 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Elranatamab and Mezigdomide for relapsed refractory multiple myeloma (rrmm).
Treatment: Elranatamab · Mezigdomide · Dexamethasone — The goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: proteasome inhibitor
Subject must have received at least one proteasome inhibitor
Must have received: lenalidomide (lenalidomide)
Subject must have received at least one proteasome inhibitor and lenalidomide
Cannot have received: mezigdomide (mezigdomide)
Subject who has had prior treatment with mezigdomide
Cannot have received: anti-BCMA agent
Subject who has had prior treatment with anti-BCMA agents (including CAR T-cell therapy, bispecifics and antibodies)
Cannot have received: allogeneic stem cell transplantation
Exception: allowed if >1 year prior and no evidence of active GVHD
Subject has previously received allogeneic stem cell transplantation within a year during prior therapy
Cannot have received: autologous stem cell transplantation
Exception: allowed if >12 weeks prior
received autologous stem cell transplantation within 12 weeks of initiating study treatment
Lab requirements
Blood counts
Absolute neutrophil count (ANC) < 1,000/µL; Platelet count: < 75,000/µL for subjects in whom < 50% of bone marrow nucleated cells are plasma cells; or a platelet count < 50,000/µL for subjects in whom ≥ 50% of bone marrow nucleated cells are plasma cells; Hemoglobin < 8 g/dL (< 4.9 mmol/L)
Kidney function
Estimated glomerular filtration rate (eGFR) < 30 mL/min or requiring dialysis
Liver function
Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN); Serum total bilirubin > 1.5 × ULN, or for participants with documented Gilbert's syndrome > 3.0 mg/dL
Cardiac function
Impaired cardiovascular function or clinically significant cardiovascular diseases, defined as any of the following within 6 months prior to enrollment: acute myocardial infarction or acute coronary syndromes, clinically significant cardiac arrhythmias, thromboembolic or cerebrovascular events, prolonged QT syndrome (or QTcF > 470 msec at screening), LVEF <40%
Subject has any of the following laboratory abnormalities: ... ANC < 1,000/µL ... Platelet count ... Hemoglobin < 8 g/dL ... eGFR < 30 mL/min or requiring dialysis ... AST or ALT > 2.5 × ULN ... Serum total bilirubin > 1.5 × ULN ... Impaired cardiovascular function or clinically significant cardiovascular diseases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06645678 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior mezigdomide, anti-BCMA agent, allogeneic stem cell transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages